Cited by 36Cardiovascular Function and Risk FactorsBlood Pressure and Hypertension StudiesCardiovascular Health and Disease Prevention

Mid- to Late-Life Time-Averaged Cumulative Blood Pressure and Late-Life Cardiac Structure, Function, and Heart Failure

Open access
Teramoto, Kanako, Nadruz Junior, Wilson, Matsushita, Kunihiro, Claggett, Brian, John, Jenine E., Skali, Hicham, Solomon, Scott, Cheng, Susan +1 more·2020·Hypertension

Abstract

Limited data exist regarding systolic blood pressure (SBP) through mid- to late-life and late-life cardiac function and heart failure (HF) risk. Among 4578 HF-free participants in the ARIC study (Atherosclerosis Risk in Communities) attending the fifth visit (2011–2013; age 75±5 years), time-averaged cumulative SBP was calculated as the sum of averaged SBPs from adjacent consecutive visits (visits 1–5) indexed to total observation time (24±1 years). Calculations were performed using measured SBPs and also incorporating antihypertensive medication specific effect constants (underlying SBP). Outcomes included comprehensive echocardiography at visit 5 and post-visit 5 incident HF, HF with preserved ejection fraction, and reduced ejection fraction. Higher cumulative SBP was associated with greater left ventricular mass and worse diastolic measures (all P <0.001), associations that were stronger with underlying compared with cumulative SBP (all P <0.05). At 5.6±1.2 years follow-up post-visit 5, higher cumulative measured and underlying SBP were associated with incident HF (hazard ratio per 10 mm Hg for measured: 1.12 [1.01–1.24]; underlying: 1.19 [95% CI, 1.10–1.30]) and HF with preserved ejection fraction (measured: 1.15 [1.00–1.33]; underlying: 1.28 [1.14–1.45]), but not HF with reduced ejection fraction (measured: 1.11 [0.94–1.32]; underlying: 1.11 [0.96–1.24]). Associations with HF and HF with preserved ejection fraction were more robust with cumulative underlying compared with measured SBP (all P <0.05). Time-averaged cumulative SBP in mid to late life is associated with worse cardiac function and risk of incident HF, especially HF with preserved ejection fraction, in late life. These associations were stronger considering underlying as opposed to measured SBP, highlighting the importance of prevention and effective treatment of hypertension to prevent late-life cardiac dysfunction and HF.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/hypertensionaha.120.14833

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The CARDIA study and ARIC cohort indicate that people with high cumulative systolic BP over many years have worse cardiac function and higher risk of incident heart failure later in life than those with lower cumulative systolic BP.

    “Mounting evidence, including data from the CARDIA study27 and the ARIC cohort28, indicates that individuals with high cumulative systolic BP levels over many years have worse cardiac function and increased risk of incident heart failure in later life compared with individuals with lower cumulative systolic BP levels.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 10

  1. [1]Kannel WB. Blood pressure as cardiovascular risk factor: prevention and treatment. JAMA. 1996; 275(20): 1571– 1576. 8622248
  2. [6]Gray L, Lee IM, Sesso HD, Batty GD. Blood pressure in early adulthood, hypertension in middle age, and future CVD mortality: HAHS (Harvard Alumni Health Study). J Am Coll Cardiol. 2011; 58(23): 2396– 403. 22115646 PMC3253414
  3. [7]Vasan RS, Massaro JM, Wilson PW, Framingham Heart Study. Antecedent blood pressure and risk of cardiovascular disease: the Framingham Heart Study. Circulation. 2002; 105(1): 48– 53. 11772875
  4. [8]Allen N, Berry JD, Ning H, Van Horn L, Dyer A, Lloyd-Jones DM. Impact of blood pressure and blood pressure change during middle age on the remaining lifetime risk for cardiovascular disease: the cardiovascular lifetime risk pooling project. Circulation. 2012; 125(1): 37– 44. 22184621 PMC3310202
  5. [12]Ghosh AK, Hardy RJ, Francis DP, Medical Research Council National Survey of Health and Development (NHSD) Scientific and Data Collection Team. Midlife blood pressure change and left ventricular mass and remodelling in older age in the 1946 British Birth Cohort Study. Eur Heart J. 2014; 35(46): 3287– 95. 25246483 PMC4258225
  6. [20]Rosamond WD, Chang PP, Baggett C, Johnson A, Bertoni AG, Shahar E, Deswal A, Heiss G, Chambless LE. Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria. Circ Heart Fail. 2012 3 1; 5(2): 152– 9. 22271752 PMC3326579
  7. [25]Beckett NS, Peters R, Fletcher AE, HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358(18): 1887– 98. 18378519
  8. [28]Mancia G, Carugo S, Grassi G, Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) Study. Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Hypertension. 2002; 39(3): 744– 9. 11897756
  9. [36]Devereux RB, Dahlof B, Gerdts E, Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004; 110(11): 1456– 62. 15326072
  10. [45]Parati G, Bilo G, Ochoa JE. Benefits of tight blood pressure control in diabetic patients with hypertension: importance of early and sustained implementation of effective treatment strategies. Diabetes Care. 2011 5; 34 Suppl 2: S297– 303. 21525472 PMC3632196

Cited by

Sorted by citations

Authors
Teramoto, K., Nadruz Junior, W., Matsushita, K., Claggett, B., John, J. E., Skali, H., Solomon, S., Cheng, S., & Shah, A. M.
Affiliations
  • Brigham and Women's Hospital (US)
  • Cardiology Division, State University of Campinas, São Paulo, Brazil (W.N.J.)
  • Johns Hopkins University (US)
  • Cedars-Sinai Medical Center (US)
Venue
Hypertension
Published
2020-09
Volume
76
Issue
3
Pages
808-818
ISSN
  • 0194-911X (ISSN-L)
  • 1524-4563
OpenAlex
W3034630844
Cited by
36
References
37
Citations by year
2026: 4 · 2025: 8 · 2024: 7 · 2023: 4 · 2022: 8 · 2021: 5
FWCI
2.63
Type
journal article
Language
en
Open access
Locations
  • Hypertension (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Institute on Aging (U54AG065141)
  • National Heart, Lung, and Blood Institute (HHSN268201700004I, R01HL143227, HHSN268201700001I, HHSN268201700005C, HHSN268201700003I, K24HL152008, HHSN268201700005I, HHSN268201700001C, R01HL143224, R01HL142983, HHSN268201700002I, R01HL150342, HHSN268201700003C, HHSN268201700002C, HHSN268201700004C, R01HL135008, T32HL094301, R01HL131532)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
Keywords
systolic blood pressure, heart failure, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, left ventricular mass, diastolic function, cardiac structure, antihypertensive drugs, older adults
MeSH terms
Heart Disease Risk Factors, Aged, Blood Pressure, Echocardiography, Female, Heart Failure, Heart Ventricles, Humans, Hypertension, Japan, Male, Organ Size, Prognosis, Public Health, Stroke Volume, Ventricular Function, Left, Early Medical Intervention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review